Better Therapeutics- Tradeable Rights - March 2021 Common Stock

The latest common stock for MCADR is $4K as of September 2023. That compares with $2K in the prior-year period — up 100.0% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's common stock moved from $2K to $4K — a 100.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

A common stock figure of $4K for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCADR's common stock ($4K), review year-over-year change from $2K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.